2025-05-29-Bernstein-agilon_health（AGL）_快速解读_AGL在战略决策会议（SDC）炉边谈话评论总结_12页_373kb

U.S. Healthcare Services - AGL Summary

Core Content

This document provides an analysis of Agilon Health (AGL), focusing on its business strategy, financial outlook, and investment implications. The summary highlights AGL's current position in the healthcare services sector, particularly in the Medicare Advantage (MA) market, and outlines the company's approach to value-based care (VBC), cost control, and risk management.

Main Points

1. AGL's Business Strategy and Turnaround

• AGL is actively working on a turnaround strategy to improve performance and margin recovery.
• The company is limiting growth in 2025/2026, not due to lack of demand, but to focus on margin improvement.
• AGL is targeting 30 to 45k new members in 2026.
• Key actions include:
  • Carving out Part D contracts, reducing exposure from 70% in 2024 to 30% in 2025.
  • Focusing on quality incentive payments, which contribute significantly to its EBITDA guidance.
  • Reducing supplemental benefits exposure, with 97% of memberships seeing a meaningful step-down.
  • Improving global cap rates and premium economics.

2. Utilization and Cost Trends

• AGL maintains a utilization rate of 5.3% for 2025, consistent with prior guidance.
• Adjusted for the midnight rule and payer bids, the utilization rate aligns with 2024 and 2023 trends at ~7%.
• Q1 2025 utilization was 5.5%, slightly above target due to flu season.

3. VBC and Payer Interest

• Strong payer interest in VBC models, especially for cost control and quality metrics (Stars).
• AGL is well-positioned to deliver value-based care through its long-term partnerships with primary care physicians (PCPs).
• These partnerships help AGL scale the business and achieve best-in-class quality and cost outcomes.

4. Financial Outlook and Valuation

• AGL expects to consume ~$110M in cash in 2025 and breakeven in 2027.
• The company is using multiple levers to improve cash flow, including advanced payments, tighter cost control, and working capital optimization.
• A DCF valuation model is used to determine the price target of $7.50, with a 219% upside from the current price of $2.35.
• The cost of equity is assumed at 17.5% until 2027, then 11.5% after breakeven.

5. Investment Implications

• Outperform rating with a price target of $7.50.
• AGL is expected to benefit from sector recovery in MA plans from 2026 to 2028.
• The company is capital light and follows a J-curve model, with breakeven expected in Year 1 at $30–60 PMPM.
• AGL believes it can generate $150–200 PMPM once the cohort matures.

Key Information

1. AGL's Unique Position

• AGL has developed a long-term partnership model with medical groups in 12 states, involving 2,200 PCPs and over 600k senior patients.
• The company helps physician groups transition from fee-for-service to risk-based models, improving both quality and cost outcomes.

2. Risk Adjustment

• AGL views risk adjustment as a "burden of illness program" to manage chronic diseases.
• They expect a net 2% increase in risk adjustment, with a ~3% headwind from v28.

3. ACO REACH Program

• AGL's ACO REACH program generates higher PMPMs due to revenue and cost synergies.
• There are no supplemental benefits or payer bidding in this program.

4. Payer Dynamics

• AGL is negotiating with MCOs to secure cost savings and quality incentives.
• The company is disciplined in contract management, and is willing to walk away from unfavorable deals.
• Payer footprint has shrunk by 10%, reflecting a strategic focus on quality and cost.

Investment Summary

• Rating: Outperform
• Price Target: $7.50
• Upside: 219%
• Market Cap: $973M
• EV: $640.63M
• Performance: YTD 23.7%, 1M -38.2%, 6M 12.4%, 12M -59.2%
• Relative Performance: 23.6% YTD, 44.7% 1M, 14.3% 6M, 70.2% 12M

Risk Considerations

• Downside risks include:
  • Accelerated utilization in MA
  • Medical margins not developing as expected
  • Unfavorable payer contract outcomes
  • Poor execution by PCP partners
  • Turnaround plans not delivering strong results

Additional Notes

• The report includes rating definitions, valuation methodology, and conflicts of interest disclosures.
• The document is distributed by various affiliates of Bernstein and Autonomous, with regulatory compliance noted for each jurisdiction.
• Legal entities and locations of analysts are disclosed based on phone number country codes.
• The report is not intended for retail investors in the PRC and is only for qualified institutional investors in Japan.

Conclusion

AGL is focused on turnaround through margin recovery, VBC model optimization, and reducing exposure to high-cost areas. The company's strategic actions and improved performance are expected to drive value creation in the coming years, supported by sector recovery and increased payer demand for VBC solutions.